KMPH News and Press, KemPharm Inc From 11/09/22

KemPharm press release ( NASDAQ: KMPH ): Q3 GAAP EPS of -$0.19 misses by $0.03 . Revenue of $2.87M (+45.7% Y/Y) misses by $0.14M . For further details see: KemPharm GAAP EPS of -$0.19 misses by $0.03, revenue of $2.87M misses by $0.14M

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 9, 2022, at 5:00 p.m. ET Significant activities underway for preparation of the arimoclomol NDA resubmission Advancing key activities to initiate a Phase 2 clinical trial of KP1077 i...

CELEBRATION, Fla., Nov. 01, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare diseases, today announced that the Company will host a confe...

CELEBRATION, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare diseases, announced its support for Niemann-Pick Awareness M...

KemPharm, Inc. ( NASDAQ: KMPH ), a company developing prodrug versions of FDA-approved drugs, announced Wednesday early results from a Phase 1 trial to support further studies for lead asset KP1077 in sleep-related disorders. The Phase 1 open-label trial involving 15 volun...

SDX administered at single doses of 80 mg and 200 mg was well-tolerated CELEBRATION, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization ...

Canaccord Genuity has launched its coverage on KemPharm, Inc. ( NASDAQ: KMPH ), a developer of enhanced versions of existing medications, with a Buy rating noting its renewed-focused on rare diseases linked to the central nervous system (CNS). The analysts Sumant Kulkarni ...

CELEBRATION, Fla., Sept. 01, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative ...

KemPharm, Inc. (KMPH) Q2 2022 Earnings Conference Call August 11, 2022 05:00 PM ET Company Participants Nichol Ochsner - Vice President-Investor Relations & Corporate Communications Travis Mickle - President & Chief Executive Officer Perry Sternberg - Chi...

KemPharm press release ( NASDAQ: KMPH ): Q2 Non-GAAP EPS of -$0.19 misses by $0.05 . Revenue of $1.3M (-89.2% Y/Y) misses by $0.45M . As of June 30, 2022, total cash, cash equivalents and investments were $114.5 million, which was a decrease of $4.6 million com...